Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
10 April 2023 - 10:30PM
Business Wire
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced the appointment of Derek J. Miller to its board of
directors effective April 10, 2023. Mr. Miller brings extensive
commercial, corporate and business development, and senior
leadership experience in oncology to the Zymeworks board of
directors.
“Derek brings over two decades of strategic, operational and
commercial leadership and deep experience in oncology to the
Zymeworks board,” said Kenneth Galbraith, Chair and CEO of
Zymeworks. “His guidance and expertise will be an important asset
for us as we work with our collaboration partners, Jazz
Pharmaceuticals and BeiGene, on development and commercialization
of zanidatamab while rapidly advancing and expanding our early
clinical and preclinical pipeline of novel antibody-drug conjugates
(ADC) and multispecific antibodies.”
“Zymeworks is at an exciting and important point in its
development as a leader in the multispecific and ADC space and I am
thrilled to be able to help support the company as it continues to
advance down this path,” said Mr. Miller. “I look forward to
collaborating with the talented team and leveraging my insights
across corporate development and commercial strategy in support of
our important mission to make a meaningful difference in the lives
of patients across the globe impacted by difficult to treat
cancers.”
Mr. Miller has been a leader in the biotechnology and
pharmaceutical sector for more than 25 years with experience in
corporate development, business development and global commercial
strategy. He is an independent commercial and business development
consultant who advises early to late-stage companies developing
platforms and assets for oncology and ultra-rare diseases. He also
currently serves as the Chief Executive Officer of a cell and gene
therapy imaging startup venture, spun out from the University of
Pennsylvania. Previously, he served as Chief Business Officer of
Aro Biotherapeutics, a spinout of Janssen Pharmaceuticals, leading
numerous strategic and operational initiatives including a
transformative collaboration with Ionis with potential revenues of
up to $1.4 billion. Mr. Miller also previously served as Chief
Business Officer of Celator Pharmaceuticals, where he led the
development of their pipeline and business development strategy
until its acquisition by Jazz Pharmaceuticals in 2016 for cash
proceeds of approximately $1.5 billion. Prior to Celator
Pharmaceuticals, Mr. Miller held a variety of marketing, sales, and
market access roles with Genentech, Centocor, and GSK. Mr. Miller
is a member of the Board of Trustees for the Eastern Pennsylvania
Chapter of the Leukemia and Lymphoma Society and serves as a mentor
for the Villanova School of Business. He received an M.B.A. from
Villanova University and Bachelor of Arts and Science degree from
the University of Delaware.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene
and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and follow
@ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or
information within the meaning of the applicable securities
legislation, including Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking statements in this press release
include, but are not limited to, statements that relate to
potential therapeutic effects and commercial potential of
zanidatamab and Zymeworks' other product candidates; Zymeworks’
expectations regarding implementation of its strategic priorities,
including those with respect to its pipeline and R&D strategy;
timing of milestones with respect to zanidatamab, ZW49 and other
potential product candidates; Zymeworks’ clinical development of
its product candidates and enrollment in its clinical trials; the
ability to advance product candidates into later stages of
development; and other information that is not historical
information. When used herein, words such as “plan”, “believe”,
“expect”, “may”, “continue”, “anticipate”, “potential”, “will”,
“progress”, and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation: clinical trials
may not demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; any of Zymeworks’ or its
partners’ product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; regulatory agencies may
impose additional requirements or delay the initiation of clinical
trials; the impact of new or changing laws and regulations; market
conditions; the impact of the COVID-19 pandemic on Zymeworks’
business, research and clinical development plans and timelines and
results of operations, including impact on its clinical trial
sites, collaborators, and contractors who act for or on Zymeworks’
behalf, may be more severe and more prolonged than currently
anticipated; and the factors described under “Risk Factors” in
Zymeworks’ quarterly and annual reports filed with the Securities
and Exchange Commission, including its Annual Report on Form 10-K
for its year ended December 31, 2022 (a copy of which may be
obtained at www.sec.gov and www.sedar.com).
Although Zymeworks believes that such forward-looking statements
are reasonable, there can be no assurance they will prove to be
correct. Investors should not place undue reliance on
forward-looking statements. The above assumptions, risks and
uncertainties are not exhaustive. Forward-looking statements are
made as of the date hereof and, except as may be required by law,
Zymeworks undertakes no obligation to update, republish, or revise
any forward-looking statements to reflect new information, future
events or circumstances, or to reflect the occurrences of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230410005136/en/
Investor Inquiries: Jack Spinks Director, Investor Relations
(604) 678-1388 ir@zymeworks.com
Media Inquiries: Diana Papove Director, Corporate Communications
(604) 678-1388 media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024